Connect with us

Technology

ConcertAI to Advance Translational and Clinical Development Solutions in Collaboration with NVIDIA

Published

7 months ago

on

CAMBRIDGE, Mass., June 2, 2024 /PRNewswire/ — ConcertAI, the leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration with NVIDIA to advance a broad set of translational and clinical development solutions within the ConcertAI CARA AI platform. This collaboration leverages NVIDIA Inference  microservices (NIM), including the recently published Llama 3 NIM, along with NVIDIA CUDA-X microservices, and the NVIDIA NeMo platform.

Over the past two years, ConcertAI has assembled the deepest and largest multi-modal oncology data repository in the industry, representing more than 8 million patients. This effort was significantly accelerated in December 2023, when the American Society of Clinical Oncology (ASCO) CancerLinQ program became a ConcertAI initiative under a long-term cooperation agreement with ASCO. In collaboration with molecular diagnostic partners and its radiological imaging business, TeraRecon, ConcertAI has established a research capability that spans genomic, transcriptomic, digital pathology, digital radiology, clinical, and social determinants of health data. This comprehensive data set covers all 50 states, offering the broadest representativeness and generalizability of any clinical data source, and forms the foundation for a range of next-generation AI models and AI-powered services. In January, the company announced its CARA AI platform, which underpins a new class of AI SaaS solutions powered by the company’s multi-modal data solutions and supports healthcare providers, research sites, and life science companies. 

As part of the collaboration, ConcertAI’s efforts to drive leading intelligence and insight in oncology research and treatment will be supported by NVIDIA’s AI expertise and infrastructure. This includes incorporating the Meta Llama 3 NIM, announced at Computex today, to drive key LLM workloads inside ConcertAI’s suite of solutions. The focus of ConcertAI’s work with NVIDIA will be on large-scale clinical data processing, multi-agent models, clinical foundation models, and related solutions that enable domain-specific AI and broad application generative AI to interoperate with unprecedented precision.

Key initiatives under this collaboration include:

High-performance AI models for clinical development solutions: This initiative will leverage NVIDIA NIMs to provide scalable, high-performance AI model deployment with low latency, enhancing flexibility, interoperability, and cost efficiency within the ConcertAI CARA AI platform. The integration will support clinical trial patient matching, protocol automation, and research site co-pilots with real-time analytics and model management for large-scale AI applications.Large-scale processing of multi-modal data: This initiative will harness NVIDIA CUDA-X microservices to accelerate ConcertAI’s large-scale data processing pipelines, significantly enhancing the largest curated oncology data set globally. By leveraging CUDA-X’s advanced computing capabilities, ConcertAI will achieve faster data processing speeds and efficiency, enabling more effective management of its vast oncology data.Development of precision oncology and medical large language models (LLMs): These foundation models, trained on ConcertAI’s industry-leading multi-modal data, will support advanced translational simulations to guide novel, first-in-human studies, clinical trial simulations and design optimizations, clinical decision augmentation support for clinical pathways, and identification of beneficial diagnostic and treatment approaches.

“Life sciences research and precision medicine both involve complex decisions based on many types of data and time points,” said Jeff Elton, PhD, CEO of ConcertAI. “For any single patient, we may have billions of unique data points, and we may be looking across millions of records, making this a domain where AI can enable insights not possible with prior technologies or methodologies. We are thrilled to work with NVIDIA to push the boundaries of what AI can achieve in oncology translational research, clinical development, and care. Our collaboration will bring unprecedented precision and new levels of efficiency to our customers’ development of new medicines, helping accelerate the improvement of outcomes for patients with the greatest unmet medical needs.”

“AI offers incredible potential to transform how medicines are designed and developed, and bringing generative AI tools to improve clinical trials is a groundbreaking and necessary step,” said Kimberly Powell, VP of Healthcare at NVIDIA. “Integrating NVIDIA’s NIM’s into ConcertAI’s SaaS and extensive multi-modal data platform will revolutionize clinical trial design and outcome prediction.”

This collaboration underscores ConcertAI’s commitment to harnessing the power of AI to drive innovation in healthcare and improve patient outcomes worldwide. Initial benefits from the collaboration will be accessible in the CARA AI cloud and solutions in Q3 of 2024.

About ConcertAI

ConcertAI is the leader in Predictive and Generative AI SaaS and Real-world Data research solutions and healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARA™ AI technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2000 health care providers, and medical societies.  CancerLinQ® is an Initiative of ConcertAI, providing oncology providers ASCO aligned automated QOPI quality solutions and SmartLinQ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, Tokyo. For more information, visit us at https://www.concertai.com. 

Media Contact: Megan Duero, megan@galestrategies.com 

View original content:https://www.prnewswire.com/news-releases/concertai-to-advance-translational-and-clinical-development-solutions-in-collaboration-with-nvidia-302161245.html

SOURCE ConcertAI

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

MagFone Christmas & New Year Sale: Unbeatable Discounts for the Holiday Season

Published

5 hours ago

on

December 22, 2024

By

The festive season is upon us, and MagFone is here to make your holidays even brighter with an exclusive Christmas & New Year sale! From incredible discounts on best-selling products to special deals on new products, MagFone is the ultimate destination for holiday shopping. From December 18, 2024 to January 6, 2025, this sale offers up to 80% off discount for everyone. Let’s dive into the details of the most awaited sale of the year.

HONGKONG, Dec. 21, 2024 /PRNewswire-PRWeb/ — What Can You Get from MagFone Christmas & New Year Sale?

New arrival – Location Changer is only $1.99 to everyone in this MagFone Christmas & New Year Grand sales. Moreover, everyone can enjoy up to 80% OFF.

1. Best-Selling Products at Up to 70% OFF

Resolving various iOS system issues or unlocking locked Apple devices like iPhone and iPad by yourself at home with MagFone’s flagship products, now available at unbeatable prices. Best-selling products such as iPhone Unlocker, Activation Unlocker, and iOS System Recovery are up for grabs with discounts of up to 70% off. Don’t miss out on this chance to get MagFone’s best-selling products at jaw-dropping prices.

MagFone iPhone Unlocker at $20.95/month and $41.95/lifetime.MagFone Activation Unlocker at $20.95/month and $41.95/lifetime.MagFone iOS System Recovery at $17.95/month and $48.95/lifetime.

2. New Arrival to Get with Only $1.99

Whether you want to change your location on your mobile device or simulate GPS movement in various games, MagFone’s new product – Location Changer – is perfect for you. Designed for both iOS and Android users, this tool comes equipped with advanced location changing features, flexible movement speed, and customizable route. With only $1.99, it is a must-have for this Christmas sale if you have the demand to change your device location.

3. 4-in-1 Bundle to Maximize Your Savings

MagFone values all loyal customers and offers exclusive pers during the Christmas & New Year sale. A super 4-in-in bundle is at reduced prices, which enables you to get all products from MagFone with an 80% off discount. This bundle includes all the tools you need, whether you’re looking to resolve various system problems and unlocking issues or change iPhone and Android device’s location. Don’t miss this chance to get all MagFone products at unbeatable prices.

MagFone Christmas & New Year Sale is a limited-time event, running from December 18, 2024 to January 6, 2025. With discount this good, products are expected to get at the lowest price this year. Don’t wait until the last minute—start shopping now to get MagFone products at the best deals.

About MagFone:

MagFone is redefining tech innovation with state-of-the-art technology and intuitive design. Whether their flagship products like iPhone Unlocker or newly-released tools like Location Changer, MagFone products are built for performance and flexibility.

YouTube: https://www.youtube.com/@magfone

Facebook: https://www.facebook.com/magfone/

X: https://x.com/magfone

Media Contact

Olivia Wood, MagFone, 86 19186985874, support@magfone.com, https://www.magfone.com/

View original content to download multimedia:https://www.prweb.com/releases/magfone-christmas–new-year-sale-unbeatable-discounts-for-the-holiday-season-302337015.html

SOURCE MagFone

Continue Reading

Technology

Dr. Ashley Milhizer Sees 300% Growth in 2024 at Real Results Medical & Aesthetics

Published

10 hours ago

on

December 21, 2024

By

After nearly two years in business, Dr. Ashley Milhizer’s Tempe-based center for naturopathic medicine and aesthetics has experienced the type of growth that rival industry titans. Real Results Medical & Aesthetics – soon to be opening a second location in Scottsdale in early 2025 – has seen an impressive 300% growth since opening their doors in March 2023.

TEMPE, Ariz., Dec. 21, 2024 /PRNewswire-PRWeb/ — After nearly two years in business, Dr. Ashley Milhizer’s Tempe-based center for naturopathic medicine and aesthetics has experienced the type of growth that rival industry titans. Real Results Medical & Aesthetics – soon to be opening a second location in Scottsdale in early 2025 – has seen an impressive 300% growth since opening their doors in March 2023.

Aside from patient referrals and cutting-edge technology, Milhizer credits social media as one of the biggest avenues for growth. “Between TikTok and Instagram we’ve amassed over 25,000 followers and that accounts for about 70% of our new business.”

Aside from patient referrals and cutting-edge technology, Milhizer credits social media as one of the biggest avenues for growth. “Between TikTok and Instagram we’ve amassed over 25,000 followers and that accounts for about 70% of our new business,” said Dr. Ashley Milhizer, Founder of Real Results Medical & Aesthetics.

On both platforms, Dr. Milhizer shares educational videos and insights into various medical & aesthetic procedures. Her engaging content not only highlights the quality of care she provides but also educates her audience on the latest trends and treatments in the field.

Originally from Michigan, and a graduate of UC Davis and the Southwest College of Naturopathic Medicine & Health Sciences, it was Dr. Milhizer’s personal experience in seeing how natural remedies can significantly impact the body that inspired her to get into the field.

“While I was in school, a friend of mine was diagnosed with stage 3 cancer and was given up to 18 months to live and I became determined to research every kind of remedy that could potentially help,” said Dr. Milhizer. “From a healthy diet, supplements and a host of other naturopathic strategies, we tried everything we could find and two months later he was in remission, and he’s still alive today.”

The power of naturopathic remedies, following an early career path in sports medicine – which enabled her to work with some of the state’s top professional athletes – is what led her to forming Real Results Medical & Aesthetics. The company’s broad depth of services is also what allowed her to expand her reach of clientele beyond athletes to everyone from the Valley’s elite CEOs and stay at home Moms to patients ranging from their early 20s to upper 80s.

The naturopathic services offered at Real Results Medical & Aesthetics include hormone optimization, peptide therapy, IV therapy, natural pain relief, weight loss, food allergy testing and overall diagnostic testing. While the aesthetics side of the business offers services such as hair restoration, skin resurfacing, botox, fillers, microneedling, RF Plasma skin resurfacing, laser treatments, vein removal and body contouring.

For more information on Real Results Medical & Aesthetics, visit www.realresultsmedical.com or call/text 480.245.5636. For ongoing news, updates and service offerings, follow Dr. Milhizer on Facebook, Instagram and LinkedIn.

Media Contact

Kendra Riley, Real Results Medical & Aesthetics, 1 4802206051, kendra@dawningpr.com 

View original content to download multimedia:https://www.prweb.com/releases/dr-ashley-milhizer-sees-300-growth-in-2024-at-real-results-medical–aesthetics-302337009.html

SOURCE Real Results Medical & Aesthetics

Continue Reading

Technology

ICEYE expands its Earth Observation capabilities with launch of two SAR satellites for mid-inclination orbit on the Bandwagon-2 mission with SpaceX

Published

15 hours ago

on

December 21, 2024

By

Mid-inclination orbit provides more SAR-imaging opportunities at middle latitudes of the globe for ICEYE customers.

HELSINKI, Finland, Dec. 21, 2024 /PRNewswire/ — ICEYE, the global leader in SAR satellite operations for Earth Observation and persistent monitoring, announced today that it has launched two new satellites to its constellation of SAR satellites. Both satellites expand the availability of ICEYE’s latest imaging technology to deliver additional 25 cm imaging capacity. The satellites were integrated via Exolaunch and launched as part of the Bandwagon-2 rideshare mission with SpaceX from Vandenberg Space Force Base in California, USA. Both satellites have established communication, and early routine operations are underway. With today’s launch, ICEYE has successfully launched 40 satellites into orbit since 2018, with nine satellites launched in 2024 alone.

The new SAR satellites were launched into mid-inclination orbits; compared to a polar orbit, these mid-inclination orbits provide more than twice the collection opportunities at middle latitudes of the globe. ICEYE customers have many areas of interest in these middle latitudes (+/- 45 degrees), and these customers will benefit from increased persistence over these regions. Customers with imaging interests outside these middle latitudes will continue to benefit from the frequent revisit enabled by ICEYE’s dozens of satellites in polar orbits. ICEYE’s unique mix of mid-inclination and polar orbits provides its customers with deep revisit capabilities for targets all around the globe. The new satellites will serve ICEYE’s commercial missions as part of the world’s largest SAR satellite constellation owned and operated by ICEYE.

Rafal Modrzewski, CEO and Co-founder of ICEYE said: “This launch marks another significant milestone in ICEYE’s ability to provide our customers with a rich diversity of collection opportunities. We bolster our industry-leading SAR constellation and expand our customers’ collection opportunities in the areas most important to them.”

Today’s launch is another step forward in ICEYE’s steady drumbeat of innovative breakthroughs in Earth Observation. This year alone, ICEYE has, for example, introduced Dwell Precise, a new 25 cm imaging mode that offers its customers the highest-fidelity 25cm imaging capability, and adds advanced capability to ICEYE’s line of Dwell products; launched an API that allows customers to directly task its SAR satellite constellation; and launched ICEYE Ocean Vision to provide actionable intelligence for maritime domain awareness.

About ICEYE

ICEYE delivers unparalleled persistent monitoring capabilities to detect and respond to changes in any location on Earth, faster and more accurately than ever before.

Owning the world’s largest synthetic aperture radar (SAR) satellite constellation, ICEYE provides objective, near real-time insights, ensuring that customers have unmatched access to actionable high-quality data, day or night, even in challenging environmental conditions. As a trusted partner to governments and commercial industries, ICEYE delivers intelligence in sectors such as insurance, natural catastrophe response and recovery, security, maritime monitoring, and finance, enabling decision-making that contributes to community resilience and sustainable development.

ICEYE operates internationally with offices in Finland, Poland, Spain, the UK, Australia, Japan, UAE, Greece, and the US.  We have more than 700 employees, inspired by the shared vision of improving life on Earth by becoming the global source of truth in Earth Observation.

Media contact: press@iceye.com

Visit www.iceye.com and follow ICEYE on LinkedIn and X for the latest updates and insights.

View original content to download multimedia:https://www.prnewswire.com/news-releases/iceye-expands-its-earth-observation-capabilities-with-launch-of-two-sar-satellites-for-mid-inclination-orbit-on-the-bandwagon-2-mission-with-spacex-302337876.html

SOURCE ICEYE

Continue Reading

Trending